DJIA 17,155.41 23.44 0.14%
NASDAQ 4,559.72 6.96 0.15%
S&P 500 2,002.24 3.26 0.16%
market minute promo

VIVUS, Inc. (NASDAQ: VVUS)

3.88 0.10 (2.65%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

VVUS $3.88 2.65%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $3.76
Previous Close $3.78
Daily Range $3.75 - $3.95
52-Week Range $3.32 - $11.64
Market Cap $401.4M
P/E Ratio -3.63
Dividend (Yield) $0.00 (0.0%)
Volume 1,285,149
Average Daily Volume 1,384,567
Current FY EPS -$1.06

Sector

Healthcare

Industry

Drugs

VIVUS, Inc. (VVUS) Description

A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products. Website: http://www.vivus.com/

News & Commentary

5 Things Arena Pharmaceuticals, Inc.'s Management Wants You to Know

Highlights from Arena Pharmaceuticals' conference call with investors.

Orexigen Therapeutics Wins Contrave Approval But Investors Should Stay Away

Doc Offers Glimpse Into Arena Pharma Weight-Loss Combination Therapy

Orexigen Falls After Approval - Why?

Arena And Vivus Ruined The FDA Approval Run Up For Orexigen

2 New Diet Drugs Coming Soon?

Orexigen Therapeutics and Novo Nordisk are close to bringing new diet drugs to market. But will doctors prescribe them?

Novo Gets Positive Vote From FDA For Anti-Obesity Treatment - Still A Long Road Ahead

Belviq Sales See Holiday Dip - Still On Track

FDA Approves Orexigen Therapeutics Inc.'s Goldilocks Obesity Drug

Orexigen and Takeda's Contrave has the right balance of efficacy and safety.

Orexigen's Obesity Pill is Approved and Stock Falls. Don't be Surprised

See More VVUS News...

VVUS's Top Competitors

VVUS $3.88 (2.65%)
Current stock: VVUS
JNJ $106.19 (0.29%)
Current stock: JNJ
NVS $94.73 (0.37%)
Current stock: NVS
RHHBY $37.37 (-0.31%)
Current stock: RHHBY